Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

• Status: RECRUITING
• Trial end date: 2030-10-18

Summary

The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer

• Phase: PHASE3

Details

• Lead Sponsor: AstraZeneca
• Treatments: abemaciclib; Anastrozole; AZD5305; AZD9833; exemestane; Fulvestrant; Letrozole; palbociclib; ribociclib